GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Cyclically Adjusted PB Ratio

DBV Technologies (DBV Technologies) Cyclically Adjusted PB Ratio : 0.21 (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Cyclically Adjusted PB Ratio?

As of today (2024-05-22), DBV Technologies's current share price is $0.611. DBV Technologies's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 was $2.98. DBV Technologies's Cyclically Adjusted PB Ratio for today is 0.21.

The historical rank and industry rank for DBV Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

DBVT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.49
Current: 0.23

During the past 13 years, DBV Technologies's highest Cyclically Adjusted PB Ratio was 0.49. The lowest was 0.00. And the median was 0.00.

DBVT's Cyclically Adjusted PB Ratio is ranked better than
80.95% of 651 companies
in the Biotechnology industry
Industry Median: 1.71 vs DBVT: 0.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

DBV Technologies's adjusted book value per share data of for the fiscal year that ended in Dec23 was $0.729. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.98 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


DBV Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for DBV Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Cyclically Adjusted PB Ratio Chart

DBV Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.81 0.55 0.55 0.32

DBV Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.32 -

Competitive Comparison of DBV Technologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, DBV Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DBV Technologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Cyclically Adjusted PB Ratio falls into.



DBV Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

DBV Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.611/2.98
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, DBV Technologies's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.729/118.3900*118.3900
=0.729

Current CPI (Dec23) = 118.3900.

DBV Technologies Annual Data

Book Value per Share CPI Adj_Book
201412 3.663 99.860 4.343
201512 7.274 100.040 8.608
201612 5.182 100.650 6.095
201712 3.119 101.850 3.626
201812 2.303 103.470 2.635
201912 2.054 104.980 2.316
202012 1.874 104.960 2.114
202112 0.903 107.850 0.991
202212 1.034 114.160 1.072
202312 0.729 118.390 0.729

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DBV Technologies  (NAS:DBVT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


DBV Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DBV Technologies (DBV Technologies) Business Description

Traded in Other Exchanges
Address
177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Executives
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Virginie Boucinha officer: Chief Financial Officer C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Michael Goller director C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Daniel Tasse director, officer: Chief Executive Officer C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809